-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, June 18 News On June 10, Weigao Orthopedics issued the "Intent Letter of Initial Public Offering and Listing on the Science and Technology Innovation Board
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
Weigao Orthopedics is a holding subsidiary of Weigao Group.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
Weigao Orthopedics was established in 2005 and is mainly engaged in the research and development, production and sales of orthopedic medical devices.
Its main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
Its main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
At the same time, the company's R&D investment has been increasing in recent years
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
The issuance of shares is planned to raise 1.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
In recent years, affected by factors such as increasing population aging, the orthopedic rehabilitation market has continued to rise, and it has become one of the hottest market segments in the medical device field
.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
The company also stated in the prospectus that the company’s bid-winning price dropped by 40%-65% in the previous procurement of orthopedic medical equipment in Jiangsu, Anhui, Fujian and other provinces
.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
In the context of the second batch of centralized procurement by countries, if the company fails to win the bid or the price of the bid drops by a large percentage while the sales volume of the bid does not meet expectations, it may have a negative impact on the company's operating performance
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
Therefore, how to minimize the pressure brought by the country's centralized procurement and maintain stable business growth will be a major test for Weigao Orthopedics after its listing
.
.
Medical Network, June 18 News On June 10, Weigao Orthopedics issued the "Intent Letter of Initial Public Offering and Listing on the Science and Technology Innovation Board
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
Weigao Orthopedics is a holding subsidiary of Weigao Group.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
Weigao Orthopedics was established in 2005 and is mainly engaged in the research and development, production and sales of orthopedic medical devices.
Its main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
Its main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
At the same time, the company's R&D investment has been increasing in recent years
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
The issuance of shares is planned to raise 1.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
In recent years, affected by factors such as increasing population aging, the orthopedic rehabilitation market has continued to rise, and it has become one of the hottest market segments in the medical device field
.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
The company also stated in the prospectus that the company’s bid-winning price dropped by 40%-65% in the previous procurement of orthopedic medical equipment in Jiangsu, Anhui, Fujian and other provinces
.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
In the context of the second batch of centralized procurement by countries, if the company fails to win the bid or the price of the bid drops by a large percentage while the sales volume of the bid does not meet expectations, it may have a negative impact on the company's operating performance
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
Therefore, how to minimize the pressure brought by the country's centralized procurement and maintain stable business growth will be a major test for Weigao Orthopedics after its listing
.
.
Medical Network, June 18 News On June 10, Weigao Orthopedics issued the "Intent Letter of Initial Public Offering and Listing on the Science and Technology Innovation Board
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
.
" According to the announcement, the company will IPO on June 21, 2021 and apply for listing on the Science and Technology Innovation Board
.
It is expected that 41,414,200 shares will be offered for subscription this time, accounting for approximately 10.
35% of the total share capital after the issuance, and the proposed fund will be 1.
88 billion yuan
.
Weigao Orthopedics is a holding subsidiary of Weigao Group.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
As of the date of announcement, Weigao Group directly and indirectly holds approximately 80.
5% of the total issued shares of Weigao Orthopedics
.
After the listing of Weigao Orthopedic Science and Technology Innovation Board, Weigao Group will reduce its shareholding to 72.
2%, and Weigao Orthopedics will remain a subsidiary of Weigao Group
.
Weigao Orthopedics was established in 2005 and is mainly engaged in the research and development, production and sales of orthopedic medical devices.
Its main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
Enterprise business enterpriseIts main products are orthopedic implanted medical devices and orthopedic surgical instruments
.
After years of development, Weigao Orthopedics has become a leading enterprise in the field of orthopedic implanted medical devices
.
From 2018 to 2020, the company achieved operating income of 1.
211 billion yuan, 1.
574 billion yuan and 1.
824 billion yuan, and net profits were 324 million yuan, 441 million yuan and 562 million yuan
.
According to the prospectus, the market share of Weigao orthopedic implant consumables was 4.
66% in 2019, ranking fifth among all manufacturers and second among domestic manufacturers
.
At the same time, the company's R&D investment has been increasing in recent years
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
.
In each period of the reporting period, the company's research and development expenses were RMB 48.
0604 million, RMB 74,091,100, and RMB 82,463,200, accounting for 3.
97%, 4.
71%, and 4.
52% of operating income, respectively
.
The issuance of shares is planned to raise 1.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
88 billion yuan, which will also be mainly invested in the expansion project of orthopedic implant products, the construction of R&D center and the construction of marketing network
.
Among them, the expansion project of orthopedic implant products is expected to increase the annual production capacity of spine, trauma, and joint orthopedic implants totaling 6.
67 million units after the completion of the project, which will further enrich the company's product line and strengthen the company's competitive advantage
.
In recent years, affected by factors such as increasing population aging, the orthopedic rehabilitation market has continued to rise, and it has become one of the hottest market segments in the medical device field
.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
Procurement Purchasing Procurement.
But at the same time, the implementation of policies such as the national "two-invoice system" and the purchase of orthopedic consumables has brought a lot of challenges to the sales and prices of Weigao orthopedic products
.
The company also stated in the prospectus that the company’s bid-winning price dropped by 40%-65% in the previous procurement of orthopedic medical equipment in Jiangsu, Anhui, Fujian and other provinces
.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
Medical equipment medical equipment medical equipment.
The drop in admission prices has also led to a drop in the ex-factory prices of products
.
In the context of the second batch of centralized procurement by countries, if the company fails to win the bid or the price of the bid drops by a large percentage while the sales volume of the bid does not meet expectations, it may have a negative impact on the company's operating performance
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
.
According to the company's calculations, if the decline in the price of the successful bid for the quantity is passed to cause the ex-factory price of the company's products to drop by 30% or more, the company's operating performance will be greatly affected
.
Therefore, how to minimize the pressure brought by the country's centralized procurement and maintain stable business growth will be a major test for Weigao Orthopedics after its listing
.
.
